EIF2AK3 and melanoma: Notably, we demonstrated that the inhibition of PERK by shRNAs or small molecular inhibitors enhanced the sensitivity of resistant PTEN-inactivated melanoma cells to BRAFi and blocked their growth in vitro and in vivo.